Activation of farnesoid X receptor downregulates visfatin and attenuates diabetic nephropathy

Molecular and Cellular Endocrinology

Volumn 419, Issue , 2016, Pages 72-82

  Zhou, Baoshang ^a   Feng, Bing ^a   Qin, Zhexue ^a   Zhao, Youguang ^b   Chen, Yu ^a   Shi, Zhengmin ^a   Gong, Yi ^a   Zhang, Jing ^a   Yuan, Fahuan ^a   Mu, Jiao ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MILITARY GENERAL HOSPITAL   (China)

Author keywords

Diabetic nephropathy; Farnesoid X receptor; Mesangial cell; Visfatin

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; FARNESOID X RECEPTOR; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CELL RECEPTOR; CYTOKINE; FARNESOID X-ACTIVATED RECEPTOR; ISOXAZOLE DERIVATIVE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; FIBROSIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CELL LINE; CYTOLOGY; DIABETIC NEPHROPATHIES; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; PROMOTER REGION;

ANIMALS; CELL LINE; CELL PROLIFERATION; CYTOKINES; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; ISOXAZOLES; MALE; MESANGIAL CELLS; MICE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROMOTER REGIONS, GENETIC; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION, GENETIC;

EID: 84949575369     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.10.001     Document Type: Article

References (40)

1. Bae E.H., Choi H.S., Joo S.Y., Kim I.J., Kim C.S., Choi J.S., Ma S.K., Lee J., Kim S.W. Farnesoid X receptor ligand prevents cisplatin-induced kidney injury by enhancing small heterodimer partner. PLoS One 2014, 9:e86553.
2. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R.E., Gay S., Kyburz D. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 2007, 56:2829-2839.
3. Cariou B., van Harmelen K., Duran-Sandoval D., van Dijk T.H., Grefhorst A., Abdelkarim M., Caron S., Torpier G., Fruchart J.C., Gonzalez F.J., Kuipers F., Staels B. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J. Biol. Chem. 2006, 281:11039-11049.
4. Chennamsetty I., Claudel T., Kostner K.M., Baghdasaryan A., Kratky D., Levak-Frank S., Frank S., Gonzalez F.J., Trauner M., Kostner G.M. Farnesoid X receptor represses hepatic human APOA gene expression. J. Clin. Invest. 2011, 121:3724-3734.
5. Choi M.E., Kim E.G., Huang Q., Ballermann B.J. Rat mesangial cell hypertrophy in response to transforming growth factor-beta 1. Kidney Int. 1993, 44:948-958.
6. Dahl T.B., Yndestad A., Skjelland M., Oie E., Dahl A., Michelsen A., Damas J.K., Tunheim S.H., Ueland T., Smith C., Bendz B., Tonstad S., Gullestad L., Froland S.S., Krohg-Sorensen K., Russell D., Aukrust P., Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007, 115:972-980.
7. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-1512.
8. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
9. Gadaleta R.M., Cariello M., Sabba C., Moschetta A. Tissue-specific actions of FXR in metabolism and cancer. Biochim. Biophys. Acta 2015, 1851:30-39.
10. Hanniman E.A., Lambert G., McCarthy T.C., Sinal C.J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 2005, 46:2595-2604.
11. Jia S.H., Li Y., Parodo J., Kapus A., Fan L., Rotstein O.D., Marshall J.C. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J. Clin. Invest. 2004, 113:1318-1327.
12. Jiang T., Wang X.X., Scherzer P., Wilson P., Tallman J., Takahashi H., Li J., Iwahashi M., Sutherland E., Arend L., Levi M. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy. Diabetes 2007, 56:2485-2493.
13. Kang Y.S., Cha D.R. The role of visfatin in diabetic nephropathy. Chonnam. Med. J. 2011, 47:139-143.
14. Kang Y.S., Song H.K., Lee M.H., Ko G.J., Cha D.R. Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2010, 89:141-149.
15. Kim da S., Kang S., Moon N.R., Park S. Central visfatin potentiates glucose-stimulated insulin secretion and beta-cell mass without increasing serum visfatin levels in diabetic rats. Cytokine 2014, 65:159-166.
16. Kralisch S., Klein J., Lossner U., Bluher M., Paschke R., Stumvoll M., Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes. Am. J. Physiol. Endocrinol. Metab. 2005, 289:E586-E590.
17. Li H., Zhang Y., Wang H., Zheng X., Chen X. Nicousamide blocks the effects of advanced glycation end products on renal cells. Eur. J. Pharmacol. 2012, 674:455-459.
18. Li L., Liu H., Peng J., Wang Y., Zhang Y., Dong J., Liu X., Guo D., Jiang Y. Farnesoid X receptor up-regulates expression of lipid transfer inhibitor protein in liver cells and mice. Biochem. Biophys. Res. Commun. 2013, 441:880-885.
19. Li Y.T., Swales K.E., Thomas G.J., Warner T.D., Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2606-2611.
20. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., Mangelsdorf D.J. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6:507-515.
21. Ma K., Saha P.K., Chan L., Moore D.D. Farnesoid X receptor is essential for normal glucose homeostasis. J. Clin. Invest. 2006, 116:1102-1119.
22. Maran R.R., Thomas A., Roth M., Sheng Z., Esterly N., Pinson D., Gao X., Zhang Y., Ganapathy V., Gonzalez F.J., Guo G.L. Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development. J. Pharmacol. Exp. Ther. 2009, 328:469-477.
23. Mu J., Feng B., Ye Z., Yuan F., Zeng W., Luo Z., Qi W. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J. Nephrol. 2011, 24:177-184.
24. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 2008, 19:433-442.
25. Park C.W., Kim J.H., Lee J.H., Kim Y.S., Ahn H.J., Shin Y.S., Kim S.Y., Choi E.J., Chang Y.S., Bang B.K. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 2000, 43:1544-1553.
26. Reutens A.T., Atkins R.C. Epidemiology of diabetic nephropathy. Contrib. Nephrol. 2011, 170:1-7.
27. Ritz E., Rychlik I., Locatelli F., Halimi S. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney Dis. 1999, 34:795-808.
28. Rizzo G., Disante M., Mencarelli A., Renga B., Gioiello A., Pellicciari R., Fiorucci S. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol. Pharmacol. 2006, 70:1164-1173.
29. Ruan X.Z., Varghese Z., Powis S.H., Moorhead J.F. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int. 2001, 60:1716-1725.
30. Shen H., Zhang Y., Ding H., Wang X., Chen L., Jiang H., Shen X. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter. Cell Physiol. Biochem. 2008, 22:1-14.
31. Sommer G., Kralisch S., Kloting N., Kamprad M., Schrock K., Kratzsch J., Tonjes A., Lossner U., Bluher M., Stumvoll M., Fasshauer M. Visfatin is a positive regulator of MCP-1 in human adipocytes in vitro and in mice in vivo. Obes. Silver Spring 2010, 18:1486-1492.
32. Sraer J.D., Delarue F., Hagege J., Feunteun J., Pinet F., Nguyen G., Rondeau E. Stable cell lines of T-SV40 immortalized human glomerular mesangial cells. Kidney Int. 1996, 49:267-270.
33. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007, 56:451-458.
34. Urizar N.L., Liverman A.B., Dodds D.T., Silva F.V., Ordentlich P., Yan Y., Gonzalez F.J., Heyman R.A., Mangelsdorf D.J., Moore D.D. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002, 296:1703-1706.
35. Wang X.X., Jiang T., Shen Y., Caldas Y., Miyazaki-Anzai S., Santamaria H., Urbanek C., Solis N., Scherzer P., Lewis L., Gonzalez F.J., Adorini L., Pruzanski M., Kopp J.B., Verlander J.W., Levi M. Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes 2010, 59:2916-2927.
36. Watanabe M., Houten S.M., Wang L., Moschetta A., Mangelsdorf D.J., Heyman R.A., Moore D.D., Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J. Clin. Invest. 2004, 113:1408-1418.
37. Wolf G., Ziyadeh F.N. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int. 1999, 56:393-405.
38. Yang W.S., Seo J.W., Han N.J., Choi J., Lee K.U., Ahn H., Lee S.K., Park S.K. High glucose-induced NF-kappaB activation occurs via tyrosine phosphorylation of IkappaBalpha in human glomerular endothelial cells: involvement of Syk tyrosine kinase. Am. J. Physiol. Ren. Physiol. 2008, 294:F1065-F1075.
39. Yao J., Zhou C.S., Ma X., Fu B.Q., Tao L.S., Chen M., Xu Y.P. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J. Gastroenterol. 2014, 20:14430-14441.
40. Zhang Y., Lee F.Y., Barrera G., Lee H., Vales C., Gonzalez F.J., Willson T.M., Edwards P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1006-1011.